CA1168582A - Dialysis solution containing glucose, amino acids and insulin - Google Patents

Dialysis solution containing glucose, amino acids and insulin

Info

Publication number: CA1168582A
Authority: CA; Canada
Prior art keywords: solution; amino acids; insulin; liter; meq
Prior art date: 1981-04-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000400439A

Other languages

English (en)

French (fr)

Inventor

Robert K. Ausman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Baxter International Inc

Original Assignee

Baxter Travenol Laboratories Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-04-27

Filing date

1982-04-05

Publication date

1984-06-05

1982-04-05 Application filed by Baxter Travenol Laboratories Inc filed Critical Baxter Travenol Laboratories Inc

1984-06-05 Application granted granted Critical

1984-06-05 Publication of CA1168582A publication Critical patent/CA1168582A/en

Status Expired legal-status Critical Current

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 44
150000001413 amino acids Chemical class 0.000 title claims abstract description 42
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 29
239000008103 glucose Substances 0.000 title claims abstract description 29
239000000385 dialysis solution Substances 0.000 title claims abstract description 26
102000004877 Insulin Human genes 0.000 title claims abstract description 22
108090001061 Insulin Proteins 0.000 title claims abstract description 22
229940125396 insulin Drugs 0.000 title claims abstract description 22
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 title abstract description 13
239000000243 solution Substances 0.000 claims abstract description 40
239000000203 mixture Substances 0.000 claims abstract description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
235000016709 nutrition Nutrition 0.000 claims abstract description 10
230000035764 nutrition Effects 0.000 claims abstract description 10
150000001720 carbohydrates Chemical class 0.000 claims abstract description 9
239000008155 medical solution Substances 0.000 claims abstract description 7
150000003839 salts Chemical class 0.000 claims abstract description 7
210000004369 blood Anatomy 0.000 claims abstract description 3
239000008280 blood Substances 0.000 claims abstract description 3
235000001014 amino acid Nutrition 0.000 claims description 39
150000002500 ions Chemical class 0.000 claims description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
239000011734 sodium Substances 0.000 claims description 4
229910052708 sodium Inorganic materials 0.000 claims description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
239000002243 precursor Substances 0.000 claims description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
239000003963 antioxidant agent Substances 0.000 claims description 2
239000011575 calcium Substances 0.000 claims description 2
229910052791 calcium Inorganic materials 0.000 claims description 2
235000018417 cysteine Nutrition 0.000 claims description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
239000011777 magnesium Substances 0.000 claims description 2
229910052749 magnesium Inorganic materials 0.000 claims description 2
229940049920 malate Drugs 0.000 claims description 2
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
230000003078 antioxidant effect Effects 0.000 claims 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
206010012601 diabetes mellitus Diseases 0.000 abstract description 6
235000020776 essential amino acid Nutrition 0.000 abstract description 2
239000003797 essential amino acid Substances 0.000 abstract description 2
230000003204 osmotic effect Effects 0.000 abstract description 2
238000000502 dialysis Methods 0.000 description 15
238000000034 method Methods 0.000 description 11
235000000346 sugar Nutrition 0.000 description 11
235000002639 sodium chloride Nutrition 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
238000000108 ultra-filtration Methods 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000001540 sodium lactate Substances 0.000 description 3
235000011088 sodium lactate Nutrition 0.000 description 3
229940005581 sodium lactate Drugs 0.000 description 3
230000001954 sterilising effect Effects 0.000 description 3
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
208000001647 Renal Insufficiency Diseases 0.000 description 2
208000020832 chronic kidney disease Diseases 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
208000028208 end stage renal disease Diseases 0.000 description 2
201000000523 end stage renal failure Diseases 0.000 description 2
230000006870 function Effects 0.000 description 2
150000002337 glycosamines Chemical class 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
230000003907 kidney function Effects 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
230000008569 process Effects 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
-1 succinate ions Chemical class 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229960005069 calcium Drugs 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229960002713 calcium chloride Drugs 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
229940052299 calcium chloride dihydrate Drugs 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
239000000004 hemodialysis solution Substances 0.000 description 1
208000021267 infertility disease Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
235000001055 magnesium Nutrition 0.000 description 1
229960002337 magnesium chloride Drugs 0.000 description 1
235000011147 magnesium chloride Nutrition 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
229940050906 magnesium chloride hexahydrate Drugs 0.000 description 1
DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
229940091250 magnesium supplement Drugs 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229960004249 sodium acetate Drugs 0.000 description 1
229960002668 sodium chloride Drugs 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
230000004102 tricarboxylic acid cycle Effects 0.000 description 1
239000002699 waste material Substances 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA000400439A 1981-04-27 1982-04-05 Dialysis solution containing glucose, amino acids and insulin Expired CA1168582A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25810581A	1981-04-27	1981-04-27
US258,105		1981-04-27

Publications (1)

Publication Number	Publication Date
CA1168582A true CA1168582A (en)	1984-06-05

Family

ID=22979115

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000400439A Expired CA1168582A (en)	1981-04-27	1982-04-05	Dialysis solution containing glucose, amino acids and insulin

Country Status (6)

Country	Link
EP (1)	EP0077354A4 (de)
JP (1)	JPS58500563A (de)
CA (1)	CA1168582A (de)
IT (1)	IT1151741B (de)
WO (1)	WO1982003773A1 (de)
ZA (1)	ZA822608B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4574085A (en) *	1981-05-15	1986-03-04	Baxter Travenol Laboratories, Inc.	Method for using dialysis solution containing glycerol
NL8701143A (nl) *	1986-05-27	1987-12-16	Sandoz Ag	Farmaceutische preparaten.
DE3812525C1 (de) *	1988-04-15	1989-06-22	Fresenius Ag, 6380 Bad Homburg, De
DE3821043A1 (de) *	1988-06-22	1989-12-28	Fresenius Ag	Dialysier- und spuel-loesung zur intraperitonealen verabreichung
US5238684A (en) *	1988-07-29	1993-08-24	University Of Florida	Compositions and methods for achieving improved physiological response to exercise
DE3940052A1 (de) *	1989-12-04	1991-06-06	Nephro Medica Pharma	Dialysier- und spuelloesung zur intraperitonealen verabreichung
AU9159891A (en) *	1990-12-31	1992-08-17	University Of Florida	Compositions and methods for achieving improved physiological response to exercice
US5290766A (en) *	1991-02-18	1994-03-01	The National Heart Foundation Of New Zealand	Cardioplegic compositions
DE4134723C1 (de) *	1991-10-21	1993-02-11	Pfrimmer Kabi Gmbh & Co Kg, 8520 Erlangen, De
SE9103395D0 (sv) *	1991-11-18	1991-11-18	Gambro Ab	System med anvaendning av ensteril medicinsk loesning innehaallande glukos eller glukosliknande aemnen samt en loesning avsedd foer detta system
JP3483885B2 (ja) *	1992-12-22	2004-01-06	バクスター、インターナショナル、インコーポレイテッド	腹膜透析患者の治療のための改良されたアミノ酸溶液
US6380163B1 (en) †	1992-12-22	2002-04-30	Baxter International Inc.	Peritoneal dialysis solutions with polypeptides
CN1110112A (zh) *	1994-04-11	1995-10-18	贾增申	一种氨基酸固体饮料及其制备方法
CA2155910C (en) *	1995-08-11	1999-12-14	George Wu	Biocompatible aqueous solution for use in continuous ambulatory peritoneal dialysis
BR9707081A (pt) *	1996-01-25	1999-05-25	Schering Ag	Soluções de injeção e infusão concentradas aperfeiçoadas para aplicação intravasal
US5948751A (en) *	1996-06-20	1999-09-07	Novo Nordisk A/S	X14-mannitol
SE9703775L (sv) *	1997-10-16	1999-04-17	Pharmalink Baslaekemedel Ab	Framställning av sterial lösningar som innehåller glukos
JP2003514014A (ja) *	1999-11-15	2003-04-15	ティーガンガル，ハナマラディ	静脈注入のためのブドウ糖およびインスリン含有液体配合物
WO2002049636A1 (en) *	2000-12-19	2002-06-27	Rajagopal Thiruvengadam	An antidiabetic composition of amino acids
SE523153C2 (sv) *	2000-12-28	2004-03-30	Gambro Lundia Ab	Metod för detoxifiering av medicinsk lösning
US20100099628A1 (en)	2007-03-02	2010-04-22	Zyto-Protec Gmbh	Carbohydrate-based peritoneal dialysis fluid comprising glutamine residue
JP5498491B2 (ja)	2008-07-07	2014-05-21	ペンテックヘルス，インコーポレイテッド	栄養組成物およびその栄養組成物の使用方法
WO2011081679A1 (en)	2010-01-04	2011-07-07	Pentec Health, Inc.	Nutritive compositions and methods of using same
WO2025087731A1 (en)	2023-10-24	2025-05-01	Gambro Lundia Ab	Compositions comprising insulin and ketones bodies to treat cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2738299A (en) *	1953-05-11	1956-03-13	Abbott Lab	Stable nutritive amino acid compositions
US3920838A (en) *	1973-09-04	1975-11-18	Flatt Jean Pierre	Amino acid therapy
US4239041A (en) *	1977-03-03	1980-12-16	Moncrief Jack W	Method for continuous ambulatory peritoneal dialysis
US4196196A (en) *	1978-06-19	1980-04-01	Tiholiz Ivan C	Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states

1982
- 1982-03-25 JP JP57501337A patent/JPS58500563A/ja active Pending
- 1982-03-25 EP EP19820901271 patent/EP0077354A4/de not_active Withdrawn
- 1982-03-25 WO PCT/US1982/000365 patent/WO1982003773A1/en not_active Ceased
- 1982-04-05 CA CA000400439A patent/CA1168582A/en not_active Expired
- 1982-04-16 ZA ZA822608A patent/ZA822608B/xx unknown
- 1982-04-23 IT IT20921/82A patent/IT1151741B/it active

Also Published As

Publication number	Publication date
JPS58500563A (ja)	1983-04-14
ZA822608B (en)	1983-03-30
IT8220921A0 (it)	1982-04-23
WO1982003773A1 (en)	1982-11-11
EP0077354A4 (de)	1983-09-30
EP0077354A1 (de)	1983-04-27
IT1151741B (it)	1986-12-24

Legal Events

Date	Code	Title	Description
2001-06-05	MKEX	Expiry

Publication	Publication Date	Title
EP0077354A4 (de)	1983-09-30	Dialyselösung glukose, aminosäuren und insulin enthaltend.
EP2322236B9 (de)	2013-01-16	Lösungen enthaltend Bikarbonat fur Dialysetherapie
AU638527B2 (en)	1993-07-01	Histidine buffered peritoneal dialysis solution
AU683878B2 (en)	1997-11-27	Method for manufacturing and storing stable bicarbonate solutions
EP1753437B1 (de)	2013-12-25	Peritonealdialyselösungen auf bicarbonatbasis
US4574085A (en)	1986-03-04	Method for using dialysis solution containing glycerol
US5945449A (en)	1999-08-31	Sterile bicarbonate concentrate
EP1511501A1 (de)	2005-03-09	Stabile bikarbonatlösung, in einem einzigen behälter sich befindend
US20020077580A1 (en)	2002-06-20	Sterile low bicarbonate dialysis concentrate solutions
JP2001520183A (ja)	2001-10-30	腹膜透析用溶液及びその製造方法
Ing et al.	1985	Bicarbonate-buffered peritoneal dialysis
US20200345762A1 (en)	2020-11-05	Method and system for providing peritoneal dialysis fluids with varying sodium concentrations
AU8392382A (en)	1982-11-24	Dialysis solution containing glucose, amino acids & insulin
Ing et al.	1984	Peritoneal dialysis using bicarbonate-buffered dialysate
EP3703758B1 (de)	2026-04-15	Verfahren und system zur bereitstellung von peritonealdialyseflüssigkeiten mit variablen kaliumkonzentrationen
CA2219822C (en)	1999-12-14	Sterile bicarbonate concentrate
Bonzel et al.	1982	Practical Problems with Continuous Ambulatory Peritoneal Dialysis in Children